Novellus Therapeutics

Biopharmaceutical company Brooklyn ImmunoTherapeutics has completed its acquisition of engineered cellular medicine company Novellus Therapeutics Limited.

This acquisition advances Brooklyn’s evolution into a platform company with a pipeline of next-generation engineered cellular, gene editing and cytokine programs.

Brooklyn ImmunoTherapeutics acquired Novellus for $125m which consisted of $23 million in cash and 7,022,230 shares of Brooklyn common stock, which were valued at a total of $102 million based on a price of approximately $14.53 per share.

Philip Lee M&A, led by Andy McConnell, was delighted to advise Novellus on this transaction.

Further information available here.

Key Contacts

Key Contacts

News and insights

Peter Crawford

Peter Crawford

It is with great sadness that we announce the unexpected and tragic passing of our colleague and dear friend Peter Crawford. Peter was with the firm for almost ten years, joining as an intern and most recently becoming a senior associate. He was an excellent lawyer...

read more
Share This